Phase I, Phase I-II
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A), advanced recurrent immune checkpoint refractory non-small cell lung cancer (NSCLC) (Part B), and metastatic pancreatic cancer (Part C) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study nab-paclitaxel or Nal-IRI/5FU/LV will be administered subsequent to CM24 and nivolumab.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Armand Russo, MD
- Carrie Fijal, MSN, AGPCNP-BC, OCN
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Joseph Kim, MD
- Kirsten Dooley
- Kristen Hoxie
- Laura Van Metre Baum, MD, MPH
- Mandy DeMerchant
- Navid Hafez, MD, MPH
- Pamela Kunz, MD
- Patricia LoRusso, DO
- Samantha Couillard
- Sara Anastasio, RN
- So Yeon Kim, MD
- Stacey Stein, MD
- Teresa White
- Virginia Syombathy
- Last Updated06/08/2023
- Study HIC#2000029869